AstraZeneca Offers Approximately $10 Billion to Acquire Rare Disease Drugmaker Rhythm
nashnova research
AstraZeneca offered roughly $10 billion — about $124 a share — for rare metabolic-disease biotech Rhythm Pharmaceuticals, a ~30% premium that would broaden its rare-disease portfolio, though a deal remains uncertain.
What price is on the table?
AstraZeneca bid $124 per share, valuing Rhythm at roughly $10 billion.
At the time of the report, Rhythm traded near $95, giving it a market cap of about $6.6 billion — the offer represents a premium of roughly 30%.
This means → AstraZeneca values Rhythm's pipeline well above where the market prices it today.
What does Rhythm actually do?
Rhythm Pharmaceuticals develops treatments for rare metabolic disorders and severe obesity.
In plain terms = this is not the mainstream weight-loss drug race; Rhythm targets genetically driven extreme metabolic conditions — a small patient pool with intense clinical need.
If completed, the deal would expand AstraZeneca's rare-disease product portfolio.
Will the deal go through?
AstraZeneca had previously approached Rhythm about an acquisition; this bid marks a renewed expression of interest.
Neither side has disclosed negotiation progress; whether a deal will close remains uncertain.
This means → repeated approaches signal sustained intent from AstraZeneca, but Rhythm has not agreed — final pricing or deal terms may still shift.
市场有风险，内容仅供研究参考，不构成投资建议。